Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2019
At a glance
- Drugs XEN 901 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Xenon Pharmaceuticals
- 06 Jan 2019 Results published in the Media Release.
- 29 Aug 2018 According to a Xenon Pharmaceuticals media release, this trial continues to make progress with dosing in MAD cohorts underway, and, to date, the data are consistent with the promising interim results presented in May 2018.
- 29 Aug 2018 According to a Xenon Pharmaceuticals media release, Xenon, along with its collaborators at King College, are exploring the use of the TMS assay in a small subset of a subjects in this ongoing XEN901 phase 1 clinical trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History